Novartis (NVS)
(Delayed Data from NYSE)
$96.73 USD
+0.85 (0.89%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $96.74 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Brokerage Reports
Novartis AG [NVS]
Reports for Purchase
Showing records 1 - 20 ( 471 total )
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 21224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 12224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 1224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 12223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended November 24.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended November 24.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended November 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Solid Tumors - Week Ended November 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for NVS 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Company: Novartis AG
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department